Thu. 30 May 2024, 4:05pm ET
Benzinga
News
Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), announced today that on May 23, 2024, it received written notice (the "Delist Notice") from The Nasdaq Stock Market ("Nasdaq") indicating the Company's continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2).